



Anne Lynn S. Chang, MD

Professor of Dermatology

CLINICAL OFFICE (PRIMARY)

- **Medical Dermatology**

450 Broadway St

Pavillion B FL 4 MC 5338

Redwood City, CA 94063

Tel (650) 723-6316 Fax (650) 721-3476

Bio

BIO

Anne Lynn S. Chang, M.D., M.A. is a board-certified dermatologist and Professor of Dermatology at Stanford University who is dedicated to improving patient care through research and education. She is the Founding Director of the Advanced Basal Cell Carcinoma Clinic, co-founding director of the Skin Longevity Program, and Director of Dermatologic Clinical Trials. Her research is both translational and clinical in nature and centers on the human genetics of healthy skin aging, skin longevity and better treatment for diseases related to aging skin, including new and better treatments for advanced basal and squamous cell skin cancers. She has experience in multiple clinical trials including investigator-initiated studies and multicenter industry-sponsored-studies leading to FDA approval for the first drugs to treat advanced basal cell and squamous cell skin cancer. In addition, she has conducted impactful translational research with collaborators into mechanisms underlying skin aging, rejuvenation and longevity. She is an affiliate of the Stanford Longevity Center. Overall, she has published over 150 articles in peer reviewed journals. She is devoted to training the next generations of clinician-researchers so that efforts to improve patient care will endure. A native of Southern California, Dr. Chang is a summa cum laude graduate of Harvard College, and a graduate of Harvard Medical School.

CLINICAL FOCUS

- Cancer > Cutaneous (Dermatologic) Oncology
- Dermatology
- Skin Cancer
- Geriatric dermatology
- basal cell carcinoma
- squamous cell carcinoma
- immunotherapy for non-melanoma skin cancer
- clinical trials
- non-melanoma skin cancer
- skin longevity

- acne rosacea
- rosacea

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Dermatology
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Director of Adult Dermatological Clinical Trials, Stanford Dermatology, (2007- present)
- Director of the Advanced Basal Cell Carcinoma Clinic, Stanford Dermatology, (2011- present)
- Dermatology Resident Physician Coach, Stanford University School of Medicine, (2023- present)
- Faculty Affiliate, Stanford Center on Longevity, (2023- present)
- Co-Founder, Stanford Skin Longevity Program, (2024- present)

HONORS AND AWARDS

- Career Development Award in the category of "Science of Human Appearance", Dermatology Foundation (2009-2012)
- Mentor Award for Medical Student, American Federation of Aging Research (2016)
- Research Scholar Award for Melanoma/Non-Melanoma Skin Cancer, American Skin Association (ASA) (2013, 2014)
- Leadership Forum Award, American Academy of Dermatology (AAD) (2014)
- Rosacea Medical Research Grant Award, National Rosacea Society (NRS) (2014-2015)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Graduate Member, American Academy of Dermatology (AAD) (2004 - 2007)
- Fellow, American Academy of Dermatology (AAD) (2008 - present)
- Core Curriculum Task Force Appointee, American Academy of Dermatology (AAD) (2015 - 2018)
- Committee on Education, Society of Investigative Dermatology (SID) (2019 - 2023)
- Member, Society of Investigative Dermatology (SID) (2021 - present)
- Co-Chair Retreat Committee (Future Leaders Virtual Retreat), Society of Investigative Dermatology (SID) (2023 - 2023)
- Advisory Council, Dermatology Foundation (2023 - present)
- Editorial Board Member, The Cureus Journal of Medical Science: Peer-Reviewed, Open Access (2023 - present)
- Editorial Board Member, Journal of the American Academy of Dermatology (JAAD) Reviews (2024 - present)

PROFESSIONAL EDUCATION

- Residency: Stanford University Dept of Dermatology (2007) CA
- Residency: UCSF Obstetrics and Gynecology (2002) CA
- Medical Education: Harvard Medical School (1999) MA
- Board Certification: Dermatology, American Board of Dermatology (2007)
- MD, Harvard Medical School , Medicine (1999)

COMMUNITY AND INTERNATIONAL WORK

- Doctor Radio, Redwood City, CA
- Doctor Radio, Redwood City, CA

- Cutting Edge Clinical Trials in Older Adults, Stanford Medicine Outpatient Center

LINKS

- Dr. Anne Chang's Lab: <http://annechangmd.stanford.edu/>
- My NCBI Publications: <https://www.ncbi.nlm.nih.gov/myncbi/anne.chang.1/bibliography/public/>

Research & Scholarship

RESEARCH INTERESTS

- Curriculum and Instruction
- Data Sciences
- Diversity and Identity
- Higher Education
- Leadership and Organization
- Lifelong Learning
- Race and Ethnicity
- Research Methods
- Science Education
- Teachers and Teaching

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My two main research interests are:

- 1) To better understand and treat patients with aggressive basal and squamous cell carcinomas

- 2) To better understand the genetic and epigenetic mechanisms of healthy human skin aging and to translate these insights into better care of skin diseases enriched in older patients, particularly skin cancer and rosacea

CLINICAL TRIALS

- Clascoterone, Recruiting
- Human Skin Aging: Clinical Parameters and Gene Expression Profiling, Not Recruiting
- Open-Label Extension Study of GDC-0449 for Previously Treated Genentech-Sponsored Ph I or II Studies, Not Recruiting
- Phase 3 Safety and Efficacy for Prevention of Basal Cell Carcinomas, Not Recruiting
- Phase I CX-4945 (Orally - Twice Daily) in Advanced Basal Cell Carcinoma, Not Recruiting
- Phase I IPI-926 in Advanced and/or Metastatic Solid Tumor Malignancies, Not Recruiting
- Phase I LY2940680 in Advanced Cancer or Advanced Basal Cell Carcinoma, Not Recruiting
- Phase I Pre-Operative Cemiplimab (REGN2810) in Recurrent Cutaneous Squamous Cell Carcinoma (CSCC), Not Recruiting
- Phase Ib Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma, Not Recruiting
- Phase II GDC-0449 for Advanced Basal Cell Carcinoma, Not Recruiting
- Phase II Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC), Not Recruiting
- Phase II REGN2810 in Advanced Basal Cell Carcinoma, Not Recruiting
- Phase II REGN2810-Fully Human Monoclonal Antibody to PD-1 in Advanced Cutaneous Squamous Cell Carcinoma, Not Recruiting

- Phase II Two Dose Levels of LDE225 in Locally Advanced or Metastatic Basal Cell Carcinoma, Not Recruiting
- Phase II Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC), Not Recruiting
- Phase III Pembrolizumab vs Placebo as in HighRisk Locally Advanced Cutaneous Squamous Cell Carcinoma, Not Recruiting
- Phase IV Cemiplimab Survivorship Epidemiology (CASE) Study, Not Recruiting
- Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors, Not Recruiting
- Pilot Sonidegib & BKM120 For the Treatment of Advanced Basal Cell Carcinomas, Not Recruiting
- Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma, Not Recruiting
- Study to Assess the Effect of Levocarnitine on Vismodegib-Associated Muscle Spasms, Not Recruiting
- Treatments Patterns, Effectiveness & Safety Outcomes in Advanced BCC & BCC Nevus Syndrome, Not Recruiting

Teaching

STANFORD ADVISEES

Med Scholar Project Advisor

Aakriti Neopaney, Twan Sia

Postdoctoral Faculty Sponsor

Johanna Sofia Rosado Lozoya

Publications

PUBLICATIONS

- **Exploratory survey study of differences in knowledge, attitudes, and practices of outpatient older adult clinical care between dermatologists, primary care physicians and geriatricians across three academic medical centers.** *BMC geriatrics*
Zhong, X., Sia, T., Perry, W. M., Li, S., Park, C., Tee, S., Kado, D. M., Yeung, H., Abuabara, K., Chang, A. L.
2026
- **Prevalence, demographic factors, co-morbidities, and treatment types associated with acanthosis nigricans in a large cross-section of 900+ transmasculine patients: Data from a single academic center 2016-2023.** *PloS one*
Sia, T., Abou-Taleb, F., Ma, C., Li, S., Chang, A. L.
2026; 21 (1): e0340907
- **Multiple adult-onset xanthogranuloma harboring KRAS G12D: a specific activating mutation with potential prognostic and treatment implications** *Journal of the American Academy of Dermatology Case Reports*
Zhong, X., Ho, P., Sia, T., Rieger, K., Brown, R., Fox, L. P., Nicholson, L., Rahman, Z., Mannis, G., Chang, A. S.
2026; In press
- **Validated, Reliable, and Novel Skin Frailty Scale for Outpatient Usage and Its Association With Age, Sex, and Non-melanoma Skin Cancer: An Observational Study** *JEADV Clinical Practice*
Ho, P., Abou-Taleb, F., Li, S., Khalili, K., Murali, V., Pathmarajah, P., Longo, S., Rahman, Z., Chiou, A., Chang, A. S.
2026
- **Acitretin chemoprevention in non-melanoma skin cancer patients with chronic hematopoietic disease: findings from three independent databases.** *The British journal of dermatology*
Sia, T., Li, S., Zhong, X., Park, C., Abou-Taleb, F., Twigg, A. R., Che, Y., Chang, A. L.
2025
- **Induced B cell receptor diversity predicts PD-1 blockade immunotherapy response.** *Proceedings of the National Academy of Sciences of the United States of America*
Che, Y., Lee, J., Abou-Taleb, F., Rieger, K. E., Satpathy, A. T., Chang, A. L., Chang, H. Y.
2025; 122 (18): e2501269122

- **Cutaneous squamous cell carcinoma of the scalp surrounding a ventriculoperitoneal shunt in a renal transplant recipient with spina bifida.** *JAAD case reports*
Ho, P., Saoub, J., Abou-Taleb, F., Fischbein, N., Chong, C., Chang, A. L.
2025; 58: 109-114
- **Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec.** *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]*
Che, Y., Abou-Taleb, F., Reddy, S. A., Chang, A. L.
2025
- **LGBTQ+-Inclusive Language in Patient-Reported Outcome Measures for Acne Vulgaris.** *JAMA dermatology*
Sia, T., Abou-Taleb, F., Yeung, H., Chang, A. L.
2024
- **Induced B-Cell Receptor Diversity Predicts PD-1 Blockade Immunotherapy Response.** *bioRxiv : the preprint server for biology*
Che, Y., Lee, J., Abou-Taleb, F., Rieger, K. E., Satpathy, A. T., Chang, A. L., Chang, H. Y.
2024
- **A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6.** *Journal of the American Academy of Dermatology*
Hughes, B. G., Guminski, A., Bowyer, S., Migden, M. R., Schmults, C. D., Khushalani, N. I., Chang, A. L., Grob, J. J., Lewis, K. D., Ansstas, G., Day, F., Ladwa, R., Stein, et al
2024
- **Novel Strategy for Strengthening Dermatoporotic Skin by Managing Cellular Senescence.** *Journal of drugs in dermatology : JDD*
Widgerow, A. D., Ziegler, M., Garruto, J. A., Ionescu, L., Shafiq, F., Meckfessel, M., Lain, E. T., Ablon, G., Harper, J., Chang, A. L., Howard-Verovic, C.
2024; 23 (9): 748-756
- **Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea.** *Frontiers in immunology*
Tu, K. Y., Jung, C. J., Shih, Y. H., Chang, A. L.
2024; 15: 1403798
- **Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial.** *Cancer medicine*
Peris, K., Inocencio, T. J., Stratigos, A. J., Lewis, K. D., Eroglu, Z., Chang, A. L., Ivanescu, C., Sekulic, A., Fury, M. G., Chen, C. I., Quek, R. G.
2024; 13 (14): e7360
- **Assessment of Mammalian Target of Rapamycin Pathway Activation in Basal Cell Carcinoma as a New Therapeutic Approach.** *The American Journal of dermatopathology*
Chang, A. L., Brown, R., Li, S., Betancourt, N., Teng, J.
2024
- **Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec.** *JAAD case reports*
Che, Y., Chong, C., Limova, M., Morris, L., Reddy, S. A., Chang, A. L.
2024; 46: 92-94
- **Shared decision-making for older adult dermatology patients (cover article)** *The Dermatologist*
Manjunath, J., Zhong, X., Onyeka, S., Chang, A. S., Butler, D.
2024; 32 (5): 33-35
- **Headache and Dermatologic Conditions** *Comorbid Conditions in the Treatment of Headache*
edited by Moskatel, L. S., Cowan, R. P.
Routledge Taylor & Francis Group.2024; 1
- **Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors.** *Annals of oncology : official journal of the European Society for Medical Oncology*
Lewis, K. D., Peris, K., Sekulic, A., Stratigos, A. J., Dunn, L., Eroglu, Z., Chang, A. L., Migden, M. R., Yoo, S. Y., Mohan, K., Coates, E., Okoye, E., Bowler, et al

2023

- **Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.** *Journal of the American Academy of Dermatology*
Stratigos, A. J., Sekulic, A., Peris, K., Bechter, O., Prey, S., Lewis, K. D., Basset-Seguín, N., Chang, A. L., Dalle, S., Fernandez Orland, A., Licitra, L., Robert, C., Ulrich, et al
2023
- **An exploratory, comparative case series of calcitonin gene-related peptide monoclonal antibodies in migraine patients with rosacea.** *The British journal of dermatology*
Sia, T., Webb, T., Li, S., Moskatel, L. S., Chang, A. L.
2023
- **Advances in cutaneous squamous cell carcinoma.** *Nature reviews. Cancer*
Winge, M. C., Kellman, L. N., Guo, K., Tang, J. Y., Swetter, S. M., Aasi, S. Z., Sarin, K. Y., Chang, A. L., Khavari, P. A.
2023
- **Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments.** *Journal of the American Academy of Dermatology*
Chang, A. L., Zaba, L., Kwong, B. Y.
2023; 88 (6): 1243-1255
- **Use of calcitonin gene-related peptide monoclonal antibodies in patients with rosacea: An exploratory, comparative case series**
Sia, T., Webb, T., Li, S., Moskatel, L., Chang, A. L.
ELSEVIER SCIENCE INC.2023: S80
- **Immunotherapy for Keratinocyte Cancers. Part 1: Immune-Related Epidemiology, Risk Factors, Pathogenesis, and Immunotherapy Management of Keratinocytic Cancers** *Journal of the American Academy of Dermatology*
Neuner, R., Lee, J., Park, C., Rieger, K. E., Colevas, A. D., Chang, A. S.
2023; 88 (6): 1225-1240
- **Correlation of Ultraviolet Radiation Levels With the Incidence of Cutaneous Squamous Cell and Merkel Cell Carcinomas in Non-sunbelt Locales in the United States: 2010-2017** *Cureus: Journal of Medical Science*
Vora, P. S., Li, S., Oh, G., Webb, T., Perry, W. M., Park, C., Chang, A. S.
2023; 15 (6): e40099
- **KEYNOTE-630: Phase 3 study of pembrolizumab as adjuvant treatment in high-risk locally advanced (LA) cutaneous squamous cell carcinoma (cSCC)**
Lee, J., Dzienis, M., Schmults, C., Schneker, M., Bratland, A., Klochikhin, M., Gifoni, M., Kirtbaya, D., Rivera-Diaz, J., Chipman, M., Geiger, J. L., Chang, A. L. S., Daniels, et al
WILEY.2022: 234-235
- **Incorporating the "4Ms" framework to improve outpatient geriatric dermatology care.** *Journal of the American Geriatrics Society*
Perry, W. M., Vora, P., Oh, G., Park, C., Chang, A. L.
2022
- **Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors**
Lewis, K. D., Perris, K., Sekulic, A., Stratigos, A., Duecker, P., Eroglu, Z., Chang, A. S., Migden, M. R., Yoo, S. Y., Mohan, K., Coates, E., Okoye, E., Baurain, et al
WILEY.2022: 105-106
- **Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3**
Migden, M. R., Schmults, C., Khushanlani, N., Guminski, A., Chang, A. L., Lewis, K., Anstas, G., Bowyer, S. E., Hughes, B. M., Schadendorf, D., Modi, B., Dunn, L., Flatz, et al
ELSEVIER.2022: S918-S919
- **Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up**
Stratigos, A., Sekulic, A., Perris, K., Bechter, O., Prey, S., Kaatz, M., Lewis, K. D., Basset-Seguín, N., Chang, A. S., Dalle, S., Orland, A., Licitra, L., Robert, et al
WILEY.2022: 38-39

- **Partnering with a senior living community to optimize tele dermatology via full body skin screening during the COVID-19 pandemic: a pilot program** *Skin Health and Disease*
Trinh, P., Yekrang, K., Phung, M., Pugliese, S., Chang, A. S., Bailey, E. E., Ko, J. M., Sarin, K. Y.
2022; 2 (3): e141
- **Recurrent bilateral cutaneous squamous cell carcinoma arising within hypertrophic lichen planus with metastasis while on cemiplimab**
Leeolou, M. C., Burgren, N. M., Lee, C. S., Momeni, A., Pinto, H., Johannet, P., Liebert, C., Nord, K. M., Chang, A. S.
JAAD case reports.
2022 ; Case Report (Volume 29): 55-58
- **Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.** *PLoS one*
Sekulic, A., Yoo, S., Kudchadkar, R., Guillen, J., Rogers, G., Chang, A. L., Guenther, S., Raskin, B., Dawson, K., Mun, Y., Chu, L., McKenna, E., Lacouture, et al
1800; 17 (1): e0262151
- **Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): follow-up at 43 months**
Ris chin, D., Khushalani, N. I., Schmults, C. D., Guminski, A., Chang, A. S., Lewis, K. D., Lim, A. M., Hernandez-Aya, L., Hughes, B. G. M., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, et al
WILEY.2021: 166
- **A 10-year retrospective cohort study of ruxolitinib and association with non-melanoma skin cancer in polycythemia vera and myelofibrosis patients.** *Journal of the American Academy of Dermatology*
Lin, J. Q., Li, S. Q., Li, S., Kiamanesh, E. F., Aasi, S. Z., Kwong, B. Y., Chang, A. L.
2021
- **Health-related Quality of Life (HRQoL) in Patients with advanced cutaneous Squamous Cell Carcinoma (CSCC) treated with Cemiplimab: Post hoc exploratory Analysis of a clinical Phase-2-Study**
Migden, M. R., Ris chin, D., Sasane, M., Mastey, V., Pavlick, A., Schmults, C. D., Chen, Z., Guminski, A., Hauschild, A., Bury, D., Chang, A. S., Rabinowits, G., Ibrahim, et al
WILEY.2021: 22
- **Antineoplastic therapy after discontinuation of sonidegib 200 mg in patients with advanced basal cell carcinoma: Results from the 42-month, randomized, double-blind BOLT study**
Gutzmer, R., Guminski, A., Foley, P., Chang, A. S., Lewis, K., Squitieri, N., Loquai, C.
MOSBY-ELSEVIER.2021: AB89
- **Primary Analysis of Phase-2-Results for Cemiplimab in Patients (pts) with locally advanced Basal Cell Carcinoma (laBCC) who progress or cannot tolerate Hedgehog Inhibitors (HHI)**
Stratigos, A. J., Sekulic, A., Peris, K., Bechter, O., Dutriaux, C., Kaatz, M., Lewis, K. D., Basset-Seguin, N., Chang, A. S., Dalle, S., Orland, A., Licitra, L., Robert, et al
WILEY.2021: 41-42
- **Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.** *Journal for immunotherapy of cancer*
Ris chin, D., Khushalani, N. I., Schmults, C. D., Guminski, A., Chang, A. L., Lewis, K. D., Lim, A. M., Hernandez-Aya, L., Hughes, B. G., Schadendorf, D., Hauschild, A., Thai, A. A., Stankevich, et al
2021; 9 (8)
- **Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.** *The Lancet. Oncology*
Stratigos, A. J., Sekulic, A., Peris, K., Bechter, O., Prey, S., Kaatz, M., Lewis, K. D., Basset-Seguin, N., Chang, A. L., Dalle, S., Orland, A. F., Licitra, L., Robert, et al
2021
- **Association of ruxolitinib with NMSCs risk in patients with polycythemia vera and myelofibrosis**
Lin, J., Li, S., Li, S., Kiamanesh, E., Aasi, S., Kwong, B., Chang, A.
ELSEVIER SCIENCE INC.2021: S43
- **A rare case of Wohlfahrtiimonas chitinoclastica infection in California**
Leeolou, M. C., Perrault, D. P., Sivaraj, D., Trotsyuk, A. A., Padmanabhan, J., Gurtner, G. C.
JAAD case reports.

2021 ; Case Report (Volume 17): 55-57

- **An exploratory, open-label study of secukinumab in patients with moderate to severe papulopustular rosacea**
Kumar, A. M., Chiou, A. S., Shih, Y., Li, S., Chang, A. S.
MOSBY-ELSEVIER.2020: AB88
- **INTERIM ANALYSIS OF PHASE 2 RESULTS FOR CEMPLIMAB IN PATIENTS WITH METASTATIC BASAL CELL CARCINOMA (MBCC) WHO PROGRESSED ON OR ARE INTOLERANT TO HEDGEHOG INHIBITORS (HHIS)**
Lewis, K., Peris, K., Sekulic, A., Stratigos, A., Dunn, L., Eroglu, Z., Chang, A., Migden, M., Li, S., Mohan, K., Coates, E., Okoye, E., Baurain, et al
BMJ PUBLISHING GROUP.2020: A260–A261
- **Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. *JAAD case reports***
Marukian, N. V., Lin, J. Q., Colevas, A. D., Coutre, S., Chang, A. L.
2020; 6 (9): 819–21
- **Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial**
Migden, M. R., Rischin, D., Hudgens, S., Chen, C., Schmults, C. D., Pavlick, A. C., Guminski, A., Hauschild, A., Chen, Z., Mastey, V., Bury, D., Chang, A. S., Rabinowits, et al
ELSEVIER.2020: S738
- **Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)**
Stratigos, A. J., Sekulic, A., Peris, K., Bechter, O., Dutriaux, C., Kaatz, M., Lewis, K. D., Basset-Seguín, N., Chang, A. S., Dalle, S., Fernandez-Orland, A., Licitra, L., Robert, et al
ELSEVIER.2020: S1175–S1176
- **Adjuvant pembrolizumab or placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma: Phase 3 KEYNOTE-630**
Chang, A. S., Daniels, G. A., Cohen, E. E., Ge, J., Gumuscu, B., Swaby, R. F., Geiger, J. L.
AMER ASSOC CANCER RESEARCH.2020
- **IL-1 beta is a potential central mediator to Papulopustular Rosacea pathology as determined by paired transcriptomic and proteomic analysis**
Harden, J., Shih, Y., Rajendran, D., Xu, J., Li, R., Hofland, H., Chang, A. L.
ELSEVIER SCIENCE INC.2020: S114
- **In-progress validation of candidate rosacea genes by targeted interrogation of alleles and assessment of rosacea comorbidities**
Kumar, A., Shih, Y., Chiou, A., Li, S., Chang, A. L.
ELSEVIER SCIENCE INC.2020: S33
- **A phase I study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma.**
Eroglu, Z., Cowey, C., Soong, J., McCormick, D., Fan, P., Chen, J., Elgendy, M., Jang, S., Chang, A. S.
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial.**
Migden, M., Rischin, D., Sasane, M., Mastey, V., Pavlick, A., Schmults, C. D., Chen, Z., Guminski, A., Hauschild, A., Bury, D., Chang, A. S., Rabinowits, G., Ibrahim, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.**
Rischin, D., Khushalani, N. I., Schmults, C. D., Guminski, A., Chang, A. S., Lewis, K. D., Lim, A., Hernandez-Aya, L., Hughes, B., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **An exploratory, open-label, investigator-initiated study of interleukin-17A (IL-17A) blockade in patients with moderate to severe papulopustular rosacea. *The British journal of dermatology***
Kumar, A. M., Chiou, A. S., Shih, Y. H., Li, S., Chang, A. L.
2020

- **Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.** *The Lancet Oncology*
Migden, M. R., Khushalani, N. I., Chang, A. L., Lewis, K. D., Schmults, C. D., Hernandez-Aya, L., Meier, F., Schadendorf, D., Guminski, A., Hauschild, A., Wong, D. J., Daniels, G. A., Berking, et al
2020
- **Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.** *Journal for immunotherapy of cancer*
Rischin, D. n., Migden, M. R., Lim, A. M., Schmults, C. D., Khushalani, N. I., Hughes, B. G., Schadendorf, D. n., Dunn, L. A., Hernandez-Aya, L. n., Chang, A. L., Modi, B. n., Hauschild, A. n., Ulrich, et al
2020; 8 (1)
- **Pathophysiology of Basal Cell Carcinoma and Its Associated Genetic Syndromes** *BASAL CELL CARCINOMA: ADVANCES IN TREATMENT AND RESEARCH*
Chang, A. S.
edited by Migden, M. R., Chen, L., Silapunt, S.
2020: 19-23
- **Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study** *British Journal of Dermatology*
Dummer, R., Guminski, A., Gutzmer, R., Lear, J. T., Lewis, K. D., Chang, A. S., Combemale, P., Dirix, L., Kaatz, M., Kudchadkar, R., Loquai, C., Plummer, R., Schulze, et al
2020; 182 (6): 1369-1378
- **Paired Transcriptomic and Proteomic Analysis Implicates IL-1 β in the Pathogenesis of Papulopustular Rosacea Explants.** *The Journal of investigative dermatology*
Harden, J. L., Shih, Y. H., Xu, J. n., Li, R. n., Rajendran, D. n., Hofland, H. n., Chang, A. L.
2020
- **A PHASE 2, MULTI-Center, PLACEBO-CONTROLLED STUDY OF Single dose Squaric Acid Dibutyl Ester (sadbe) to reduce frequency of outbreaks IN SUBJECTS WITH RECURRENT HERPES LABIALIS.** *Journal of the American Academy of Dermatology*
Chang, A. L., Honari, G. n., Guan, L. n., Zhao, L. n., Palli, M. A., Horn, T. D., Dudek, A. Z., McTavish, H. n.
2020
- **Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC)**
Rischin, D., Khushalani, N. I., Schmults, C. D., Guminski, A., Chang, A. S., Lewis, K. D., Lim, A. M., Hernandez-Aya, L., Hughes, B. M., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, et al
OXFORD UNIV PRESS.2019
- **KEYNOTE-630: phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma**
Geiger, J., Daniels, G., Cohen, E., Ge, J., Gumuscu, B., Swaby, R., Chang, A.
BMC.2019
- **Alterations of Immune and Keratinization Gene Expression in Papulopustular Rosacea by Whole Transcriptome Analysis.** *The Journal of investigative dermatology*
Shih, Y., Xu, J., Kumar, A., Li, R., Chang, A. L.
2019
- **Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti-PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)**
Rischin, D., Lim, A. M., Schmults, C. D., Khushalani, N. I., Hughes, B. G., Schadendorf, D., Dunn, L. A., Chang, A. S., Hauschild, A., Ulrich, C., Eigentler, T., Migden, M. R., Pavlick, et al
OXFORD UNIV PRESS.2019
- **Exploratory study to examine the gene expression effects of retinol on aging-related molecular pathways in individuals of East Asian descent**
Guan, L., Zhao, L., Xu, J., Li, R., Kern, D., Knaggs, H., Chang, A. S.
MOSBY-ELSEVIER.2019: AB64

- **A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas**
Chang, A., Duy Tran, Cannon, J., Li, S., Jeng, M., Rieger, K., Reddy, S., Sarin, K., Colevas, D.
MOSBY-ELSEVIER.2019: AB8
- **Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase 2 randomised, double-blind BOLT study.** *The British journal of dermatology*
Dummer, R., Guminski, A., Gutzmer, R., Lear, J. T., Lewis, K. D., Chang, A. L., Combemale, P., Dirix, L., Kaatz, M., Kudchadkar, R., Loquai, C., Plummer, R., Schulze, et al
2019
- **Genetic mutations underlying phenotypic plasticity in basosquamous carcinoma**
Chiang, A., Tan, C., Kuonen, F., Hodgkinson, L., Chiang, F., Cho, R., Tang, J., Chang, A., Rieger, K., Oro, A., Sarin, K.
ELSEVIER SCIENCE INC.2019: S295
- **Quantitative analysis of differentially expressed proteins in papulopustular rosacea**
Harden, J., Shih, Y., Rajendran, D., Hofland, H., Chang, A.
ELSEVIER SCIENCE INC.2019: B25
- **An exploratory open label phase 1b study of secukinumab in patients with moderate to severe papulopustular rosacea**
Kumar, A., Chiou, A., Shih, Y., Li, S., Chang, A.
ELSEVIER SCIENCE INC.2019: B15
- **Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma** *AMERICAN JOURNAL OF CLINICAL DERMATOLOGY*
Patel, R., Chang, A. S.
2019; 20 (4): 477–82
- **Incidence of Perineural Invasion with Hedgehog Pathway Inhibitors in Orbital and Periorbital Basal Cell Carcinoma**
Chandramohan, A., Nair, A., Chang, A., Kossler, A. L.
ASSOC RESEARCH VISION OPHTHALMOLOGY INC.2019
- **Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.**
Guminski, A., Lim, A., Khushalani, N. I., Schmults, C. D., Hernandez-Aya, L., Modi, B., Dunn, L., Hughes, B., Chang, A. S., Hauschild, A., Migden, M., Gutzmer, R., Alam, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high risk, locally advanced cutaneous squamous cell carcinoma.**
Geiger, J., Daniels, G. A., Cohen, E. E. W., Ge, J., Gumuscu, B., Swaby, R. F., Chang, A. S.
AMER SOC CLINICAL ONCOLOGY.2019
- **Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).**
Migden, M., Khushalani, N. I., Chang, A. S., Rischin, D., Schmults, C. D., Hernandez-Aya, L., Meier, F., Schadendorf, D., Guminski, A., Hauschild, A., Wong, D. J. L., Daniels, G. A., Berking, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Pembrolizumab with or without vismodegib for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study**
Chang, A., Tran, D. C., Cannon, J., Li, S., Jeng, M., Rieger, K., Sarin, K. Y., Yost, K., Satpathy, A., Reddy, S., Colevas, A.
ELSEVIER SCIENCE INC.2019: S92
- **Exploratory study to examine the gene expression effects of topical retinol on aging-related pathways in individuals of East Asian descent**
Guan, L., Zhao, L., Xu, J., Li, R., Kern, D., Knaggs, H., Chang, A.
ELSEVIER SCIENCE INC.2019: S117
- **Alterations of gene expression in papulopustular rosacea by whole transcriptome analysis**
Shih, Y., Xu, J., Kumar, A., Li, R., Chang, A.
ELSEVIER SCIENCE INC.2019: S170

- **Interim analysis of phase 2 results for Cemiplimab, a human monoclonal antibody to programmed death-1 (PD-1), in patients with locally advanced cutaneous squamous cell carcinoma**
Migden, M. R., Berking, C., Chang, A. S., Eigentler, T. K., Hauschild, A., Hernandez-Aya, L., Khushalani, N., Lewis, K. D., Meier, F., Modi, B., Rischin, D., Schadendorf, D., Schmults, et al
WILEY.2019: 161–62
- **Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment** *DERMATOLOGIC SURGERY*
Nayyar, P., Chang, A. S., Sarin, K., Ratner, D.
2019; 45 (4): 608–10
- **Enhancer Connectome Nominates Target Genes of Inherited Risk Variants from Inflammatory Skin Disorders** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*
Jeng, M. Y., Mumbach, M. R., Granja, J. M., Satpathy, A. T., Chang, H. Y., Chang, A. S.
2019; 139 (3): 605–14
- **Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.** *American journal of clinical dermatology*
Patel, R., Chang, A. L.
2019
- **Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Chang, A. S., Tran, D. C., Cannon, J. G. D., Li, S., Jeng, M., Patel, R., Van der Bokke, L., Pague, A., Brotherton, R., Rieger, K. E., Satpathy, A. T., Yost, K. E., Reddy, et al
2019; 80 (2): 564–66
- **Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion.** *Nature biotechnology*
Satpathy, A. T., Granja, J. M., Yost, K. E., Qi, Y. n., Meschi, F. n., McDermott, G. P., Olsen, B. N., Mumbach, M. R., Pierce, S. E., Corces, M. R., Shah, P. n., Bell, J. C., Jhutti, et al
2019; 37 (8): 925–36
- **Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma** *Journal of INVESTIGATIVE DERMATOLOGY | Original Article | Carcinogenesis/Tumorigenesis*
Chiang, A., Tan, C. Z., Kuonen, F., Hodgkinson, L. M., Chiang, F., Cho, R. J., South, A. P., Tang, J. Y., Chang, A. S., Rieger, K. E., Oro, A. E., Sarin, K. Y.
2019; 139 (11): 2263-2271. E5
- **Heterogeneity in old fibroblasts is linked to variability in reprogramming and wound healing.** *Nature*
Mahmoudi, S. n., Mancini, E. n., Xu, L. n., Moore, A. n., Jahanbani, F. n., Hebestreit, K. n., Srinivasan, R. n., Li, X. n., Devarajan, K. n., Prélôt, L. n., Ang, C. E., Shibuya, Y. n., Benayoun, et al
2019; 574 (7779): 553–58
- **Clonal replacement of tumor-specific T cells following PD-1 blockade.** *Nature medicine*
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y. n., Wang, C. n., Kageyama, R. n., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., Gupta, R. K., Curtis, C. n., Bucktrout, et al
2019
- **Reply to: "Use of immortal time within survival analysis"** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Lee, C., Li, S., Duy Cong Tran, Zhu, G., Kim, J., Kwong, B. Y., Chang, A. S.
2019; 80 (1): E19–E20
- **Enhancer connectome nominates target genes of inherited risk variants from inflammatory skin disorders.** *The Journal of investigative dermatology*
Jeng, M. Y., Mumbach, M. R., Granja, J. M., Satpathy, A. T., Chang, H. Y., Chang, A. L.
2018
- **Response to the Letter to the Editor entitled, "Use of immortal time within survival analysis": JAAD-D-18-01157.** *Journal of the American Academy of Dermatology*
Min Lee, C. K., Li, S., Tran, D. C., Zhu, G. A., Kim, J., Kwong, B. Y., Chang, A. L.
2018

- **A case of combination PD-1 inhibitor and intralesional 5-fluorouracil for high-frequency nonmelanoma skin cancers in an immunocompromised patient**
Duy Tran, Lee, C., Colevas, A., Chang, A.
MOSBY-ELSEVIER.2018: AB6
- **Reaction patterns of dermatitis arising during PD-1/PD-L1 inhibitor therapy and association with tumor response**
Lee, C., Li, S., Zhu, A., Kim, J., Duy Tran, Kwong, B., Chang, A.
MOSBY-ELSEVIER.2018: AB239
- **Differences in skin aging characteristics in women of East Asian versus European descent residing in the same geographic location**
Guan, L., Zhu, A., Li, S., Montana, M., Kern, D., Knaggs, H., Chang, A.
MOSBY-ELSEVIER.2018: AB108
- **Recurrence outcomes for nonmelanoma skin cancer after adjuvant radiation**
Cannon, J., Li, S., Chang, A.
MOSBY-ELSEVIER.2018: AB241
- **Levocarnitine for vismodegib-associated muscle spasms: A pilot randomized, double-blind, placebo-controlled, investigator-initiated trial**
Chang, A., Cannon, J., Tran, D., Li, S.
MOSBY-ELSEVIER.2018: AB178
- **Retrospective comparison of the clinical effects of programmed death protein 1 inhibitors to treat melanoma versus nonmelanoma skin cancer**
Jin, M., Li, S., Duy Tran, Henry, S., Wood, D., Chang, A.
MOSBY-ELSEVIER.2018: AB246
- **An exploratory, open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas**
Duy Tran, Zhu, A., Chang, A.
MOSBY-ELSEVIER.2018: AB38
- **Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility** *JCI INSIGHT*
Cho, H. G., Kuo, K. Y., Li, S., Bailey, I., Aasi, S., Chang, A. S., Oro, A. E., Tang, J. Y., Sarin, K. Y.
2018; 3 (15)
- **Unintended widespread facial autoinoculation of varicella by home microneedling roller device.** *JAAD case reports*
Leatham, H., Guan, L., Chang, A. L.
2018; 4 (6): 546–47
- **Hedgehog Pathway Inhibitors as Neoadjuvant Therapy for Orbital/Periorbital Basal Cell Carcinoma**
Chandramohan, A., Nair, A., Chang, A. L., Kossler, A.
ASSOC RESEARCH VISION OPHTHALMOLOGY INC.2018
- **Levocarnitine for vismodegib-associated muscle spasms: a pilot randomized, double-blind, placebo-controlled, investigator-initiated trial** *JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY*
Cannon, J. D., Tran, D. C., Li, S., Chang, A. S.
2018; 32 (7): E298–E299
- **Genetic fine-mapping of the lowan SNCA gene triplication in a patient with Parkinson's disease** *NPJ PARKINSONS DISEASE*
Zafar, F., Valappil, R., Kim, S., Johansen, K. K., Chang, A. S., Tetrud, J. W., Eis, P. S., Hatchwell, E., Langston, J., Dickson, D. W., Schule, B.
2018; 4: 18
- **PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.** *The New England journal of medicine*
Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., Chung, C. H., Hernandez-Aya, L., Lim, A. M., Chang, A. L., Rabinowits, G., Thai, A. A., Dunn, et al
2018
- **Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study.** *Journal of the American Academy of Dermatology*
Min Lee, C. K., Li, S., Tran, D. C., Zhu, G. A., Kim, J., Kwong, B. Y., Chang, A. L.

2018

- **Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC)**
Rischin, D., Migden, M., Chang, A., Chung, C. H., Dunn, L., Guminski, A., Hauschild, A., Hernandez-Aya, L., Hughes, B., Lewis, K. D., Lim, A., Modi, B., Schadendorf, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility**
Cho, H., Kuo, K., Li, S., Bailey-Healy, I., Aasi, S., Chang, A., Oro, A. E., Epstein, E., Tang, J., Sarin, K. Y.
ELSEVIER SCIENCE INC.2018: S28
- **Enhancer connectome functionally interrogates GWAS-identified intergenic SNPs associated with inflammatory skin conditions**
Jeng, M. Y., Mumbach, M. R., Granja, J. M., Satpathy, A. T., Chang, H., Chang, A.
ELSEVIER SCIENCE INC.2018: S140
- **Adjuvant radiotherapy following resection for non-melanoma skin cancer: A retrospective analysis of recurrence risk at Stanford**
Cannon, J. D., Li, S., Hara, W., Chang, A.
ELSEVIER SCIENCE INC.2018: S93
- **An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Tran, D., Moffat, A., Brotherton, R., Pague, A., Zhu, G., Chang, A. S.
2018; 78 (5): 1011–13
- **Association of tumor response to PD-1/PD-L1 immunotherapy and type of dermatitis that arises after the immunotherapy**
Lee, C., Li, S., Tran, D., Zhu, A., Kim, J., Kwong, B., Chang, A.
ELSEVIER SCIENCE INC.2018: S90
- **Differences in skin aging characteristics in women of East Asian versus European descent residing in the same geographic location**
Guan, L., Zhu, G. A., Li, S., Montana, M., Kern, D., Knaggs, H. E., Chang, A.
ELSEVIER SCIENCE INC.2018: S216
- **Emerging trends in the treatment of advanced basal cell carcinoma.** *Cancer treatment reviews*
Migden, M. R., Chang, A. L., Dirix, L., Stratigos, A. J., Lear, J. T.
2018; 64: 1-10
- **Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.** *Journal of the European Academy of Dermatology and Venereology : JEADV*
Lear, J. T., Migden, M. R., Lewis, K. D., Chang, A. L., Guminski, A., Gutzmer, R., Dirix, L., Combemale, P., Stratigos, A., Plummer, R., Castro, H., Yi, T., Mone, et al
2018; 32 (3): 372-381
- **Levocarnitine for vismodegib-associated muscle spasms: a pilot randomized, double-blind, placebo-controlled, investigator-initiated trial.** *Journal of the European Academy of Dermatology and Venereology : JEADV*
Cannon, J. G., Tran, D. C., Li, S., Chang, A. S.
2018
- **A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.** *JAAD case reports*
Cannon, J. G., Russell, J. S., Kim, J. n., Chang, A. L.
2018; 4 (3): 248–50
- **Evidence-based update on rosacea comorbidities and their common physiologic pathways.** *Journal of the American Academy of Dermatology*
Holmes, A. D., Spoenclin, J., Chien, A. L., Baldwin, H., Chang, A. L.
2018; 78 (1): 156-166
- **Old fibroblasts secrete inflammatory cytokines that drive variability in reprogramming efficiency and may affect wound healing between old individuals (Preprint)** *bioRxiv, THE PREPRINT SERVER FOR BIOLOGY*
Mahmoudi, S., Mancini, E., Moore, A., Xu, L., Jahanbani, F., Hebestreit, K., Srinivisan, R., Li, X., Devarajan, K., Prelot, L., Ang, C. E., Shibuya, Y., Benayoun, et al

2018

- **Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.** *Journal of the American Academy of Dermatology*
Chang, A. L., Tran, D. C., Cannon, J. G., Li, S. n., Jeng, M. n., Patel, R. n., Van der Bokke, L. n., Pague, A. n., Brotherton, R. n., Rieger, K. E., Satpathy, A. T., Yost, K. E., Reddy, et al
2018
- **A daily skincare regimen with a unique ceramide and filaggrin formulation rapidly improves chronic xerosis, pruritus, and quality of life in older adults** *GERIATRIC NURSING*
Chang, A. S., Chen, S. C., Osterberg, L., Brandt, S., von Grote, E. C., Meckfessel, M. H.
2018; 39 (1): 24–28
- **An 18-year retrospective study on the outcomes of keratoacanthomas with different treatment modalities at a single academic centre.** *The British journal of dermatology*
Tran, D. C., Li, S., Henry, S., Wood, D. J., Chang, A. L.
2017; 177 (6): 1749-1751
- **Initial in vitro functional characterization of serum exosomal microRNAs from patients with metastatic basal cell carcinoma.** *The British journal of dermatology*
Chang, J., Tran, D. C., Zhu, G. A., Li, R., Whitson, R., Kim, Y. H., Gupta, A., Afshari, A., Antes, T., Spitale, R. C., Chang, A. L.
2017; 177 (5): e187-e190
- **Commentary on Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment** *DERMATOLOGIC SURGERY*
Chang, A. S.
2017; 43 (7): 991–92
- **An 18-year retrospective study on the outcomes of keratoacanthomas with different treatment modalities at a single academic center**
Duy Tran, Li, S., Henry, S., Wood, D., Chang, A.
MOSBY-ELSEVIER.2017: AB39
- **PD-1 inhibition for cutaneous squamous cell carcinoma: A study of six consecutive cases**
Duy Tran, Colevas, A., Chang, A.
MOSBY-ELSEVIER.2017: AB193
- **A randomized, double-blind, placebo-controlled crossover trial of levocarnitine for vismodegib-associated muscle spasms (NCT1893892)**
Cannon, J. D., Tran, D. C., Li, S., Chang, A. S.
ELSEVIER SCIENCE INC.2017: S51
- **Genetic drivers of basosquamous carcinoma**
Chiang, A., Tan, C., Rieger, K., Cho, R., Chang, A. S., Tang, J. Y., Oro, A., Sarin, K. Y.
ELSEVIER SCIENCE INC.2017: S18
- **Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.** *JAMA dermatology*
Chang, J., Zhu, G. A., Cheung, C., Li, S., Kim, J., Chang, A. L.
2017
- **Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes.** *Head & neck*
Amoils, M., Lee, C. S., Sunwoo, J., Aasi, S. Z., Hara, W., Kim, J., Sirjani, D., Colevas, A. D., Chang, A. L., Divi, V.
2017
- **Elder mistreatment training gaps among dermatology resident physicians and opportunity to improve care of a vulnerable population: A cross-sectional study.** *Journal of the American Academy of Dermatology*
Danesh, M., Chang, J., Millsop, J. W., Saric, S., Li, S., Chang, A. L.
2017; 76 (2): 360-362
- **Reversible cutaneous side effects of vismodegib treatment.** *Cutis*
Kwong, B. n., Danial, C. n., Liu, A. n., Chun, K. A., Chang, A. L.

2017; 99 (3): E19–E20

- **Safety and efficacy of vismodegib in patients aged ≥ 65 years with advanced basal cell carcinoma.** *Oncotarget*
Chang, A. L., Lewis, K. D., Arron, S. T., Migden, M. R., Solomon, J. A., Yoo, S., Day, B. M., McKenna, E. F., Sekulic, A.
2016; 7 (46): 76118-76124
- **Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.** *JAMA dermatology*
Tran, D. C., Colevas, A. D., Chang, A. L.
2016
- **Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma: Not a Case-Control Study Reply** *JAMA DERMATOLOGY*
Li, S., Chang, A. S.
2016; 152 (10): 1173
- **Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials** *ORPHANET JOURNAL OF RARE DISEASES*
Chang, A. S., Arron, S. T., Migden, M. R., Solomon, J. A., Yoo, S., Day, B., McKenna, E. F., Sekulic, A.
2016; 11: 120
- **Sonidegib safety in patients with locally advanced Basal Cell Carcinoma and efficacy based on tumor aggressiveness**
Lear, J., Guminski, A., Gutzmer, R., Migden, M., Kudchadkar, R., Lewis, K., Dirix, L., Plummer, R., Stratigos, A., Chang, A. L., Trefzer, U., Loquai, C., Kaatz, et al
LIPPINCOTT WILLIAMS & WILKINS.2016: E72–E73
- **Male gender is a significant risk factor for the development of multiple basal cell cancers**
Batra, P., Kuo, K., Chahal, H. S., Rieger, K., Oro, A. E., Chang, A. S., Li, S., Tang, J., Sarin, K.
ELSEVIER SCIENCE INC.2016: B5
- **Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis**
Dummer, R., Migden, M., Guminski, A., Gutzmer, R., Kudchadkar, R., Lewis, K., Dirix, L., Combemale, P., Trefzer, U., Loquai, C., Kaatz, M., Chang, A. L., Stratigos, et al
LIPPINCOTT WILLIAMS & WILKINS.2016: E3
- **Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC)** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Kwon, G. P., Ally, M., Bailey-Healy, I., Oro, A. E., Kim, J., Chang, A., Aasi, S., Tang, J. Y.
2016; 75 (1): 213–15
- **The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Dummer, R., Guminski, A., Gutzmer, R., Dirix, L., Lewis, K. D., Combemale, P., Herd, R. M., Kaatz, M., Loquai, C., Stratigos, A. J., Schulze, H., Plummer, R., Gogov, et al
2016; 75 (1): 113–+
- **Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.**
Dummer, R., Migden, M., Guminski, A., Gutzmer, R., Kudchadkar, R., Lewis, K. D., Dirix, L., Combemale, P., Trefzer, U., Loquai, C., Kaatz, M., Chang, A. L. S., Stratigos, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma** *JAMA DERMATOLOGY*
Mohan, S. V., Chang, J., Li, S., Henry, A. S., Wood, D. J., Chang, A. L.
2016; 152 (5): 527-532
- **PDL1 and CD8 expression in basal cell carcinoma correlates with response to Hedgehog inhibitor therapy**
Chang, J., Zhu, G. A., Li, S., Kim, J., Chang, A. S.
ELSEVIER SCIENCE INC.2016: S44
- **Dermatology resident physician training and readiness to identify and manage elder mistreatment**
Chang, J., Danesh, M., Endo, J., Osterberg, L., Millsop, J., Aughenbaugh, W., Schillinger, E., Singh, B., Sussman, R., Chang, A. S.

MOSBY-ELSEVIER.2016: AB25

- **Identification of metastasis-associated microRNAs in basal cell carcinoma**
Chang, J., Zhu, G. A., Li, R., Antes, T., Spitale, R., Chang, A. S.
MOSBY-ELSEVIER.2016: AB199
- **Expanding Our Understanding of Human Skin Aging** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*
Chang, A. S.
2016; 136 (5): 897–99
- **Dermatology resident physician training and readiness to identify and manage elder mistreatment**
Chang, J., Danesh, M., Hibler, B., Saric, S., Millsop, J., Endo, J., Aughenbaugh, W., Chang, A. S.
ELSEVIER SCIENCE INC.2016: S27
- **Efficacy and safety of sonidegib in patients (pts) with nevoid basal cell carcinoma syndrome (NBCCS)**
Lear, J., Migden, M., Guminski, A., Dirix, L., Chang, A. S., Burnett, P., Sellami, D., Gutzmer, R., Stingl, G., Dummer, R.
MOSBY-ELSEVIER.2016: AB196
- **Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.** *JAMA dermatology*
Ally, M. S., Ransohoff, K., Sarin, K., Atwood, S. X., Rezaee, M., Bailey-Healy, I., Kim, J., Beachy, P. A., Chang, A. L., Oro, A., Tang, J. Y., Colevas, A. D.
2016; 152 (4): 452-456
- **An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib** *CLINICAL CANCER RESEARCH*
Danial, C., Sarin, K. Y., Oro, A. E., Chang, A. L.
2016; 22 (6): 1325-1329
- **Regionally Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck: Survival and High-Risk Features**
Amoils, M., Lee, C. S., Sunwoo, J., Aasi, S. Z., Hara, W., Kim, J., Sirjani, D., Colevas, A. D., Chang, A. S., Divi, V.
ELSEVIER SCIENCE INC.2016: 954
- **Estimation of individual cumulative ultraviolet exposure using a geographically-adjusted, openly-accessible tool.** *BMC dermatology*
Zhu, G. A., Raber, I., Sakshuwong, S., Li, S., Li, A. S., Tan, C., Chang, A. L.
2016; 16 (1): 1-?
- **A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor**
Chang, A. S., Kim, J., Luciano, R., Sullivan-Chang, L., Colevas, A. D.
JAMA Dermatology.
2016 ; Observation (Volume 152, Issue 1): 106-108
- **Genetic Basis of Healthy Skin Aging** *Textbook of Aging Skin*
edited by Farage, M. A., Miller, K. W., Maibach, H. I.
Springer Berlin, Heidelberg.2016; 2: 1525-1528
- **Major Changes in Skin Function in the Elderly and Their Contributions to Common Clinical Challenges** *Textbook of Aging Skin*
edited by Farage, M. A., Miller, K. W., Maibach, H. I.
Springer Berlin, Heidelberg.2016; 2: 43-53
- **Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma.** *JAAD case reports*
Mohan, S. V., Kuo, K. Y., Chang, A. L.
2016; 2 (1): 13-15
- **Novel Gene Expression Profile of Women with Intrinsic Skin Youthfulness by Whole Transcriptome Sequencing.** *PLoS one*
Xu, J., Spitale, R. C., Guan, L., Flynn, R. A., Torre, E. A., Li, R., Raber, I., Qu, K., Kern, D., Knaggs, H. E., Chang, H. Y., Chang, A. L.
2016; 11 (11)
- **Invited Commentary on Dermatological disease in the older age group: a cross-sectional study in aged care facilities** *British Medical Journal (BMJ) Publishing Group Limited*

- Deo, M. S., Kerse, N., Vandal, A. C., Jarrett, P.
2015; 5 (12): e009941
- **Mutations in the Kinetochores Gene KNSTRN in Basal Cell Carcinoma.** *journal of investigative dermatology*
Jaju, P. D., Nguyen, C. B., Mah, A. M., Atwood, S. X., Li, J., Zia, A., Chang, A. L., Oro, A. E., Tang, J. Y., Lee, C. S., Sarin, K. Y.
2015; 135 (12): 3197-3200
 - **IMPROVEMENT OF SIGNS OF XEROSIS AND PRURITUS IN ELDERLY SUBJECTS USING A SKINCARE REGIMEN FORMULATED WITH FILAGGRIN AND CERAMIDE TECHNOLOGY**
Brandt, S., Chang, A. S., Meckfessel, M.
OXFORD UNIV PRESS INC.2015: 471
 - **Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.** *JAMA dermatology*
Pollom, E. L., Bui, T. T., Chang, A. L., Colevas, A. D., Hara, W. Y.
2015; 151 (9): 998-1001
 - **A Qualitative Comparison of Symptoms and Impact of Varying Stages of Basal Cell Carcinoma.** *Dermatology and therapy*
Steenrod, A. W., Smyth, E. N., Bush, E. N., Chang, A. L., Arron, S. T., Helfrich, Y. R., Von Hoff, D. D., Brail, L. H., Coyne, K. S.
2015; 5 (3): 183-199
 - **RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.** *Cancer research*
Zhao, X., Ponomarev, T., Ornell, K. J., Zhou, P., Dabral, S. K., Pak, E., Li, W., Atwood, S. X., Whitson, R. J., Chang, A. L., Li, J., Oro, A. E., Chan, et al
2015; 75 (17): 3623-3635
 - **The role of the dermatologist in detecting elder abuse and neglect.** *Journal of the American Academy of Dermatology*
Danesh, M. J., Chang, A. L.
2015; 73 (2): 285-93
 - **Dermatology practices: Effects of geographic distribution on health care disparities**
Pyles, M., Nkansah-Mahaney, N., Chang, A. S., Resneck, J.
NATURE PUBLISHING GROUP.2015: S3
 - **Rolling the Genetic Dice: Neutral and Deleterious Smoothed Mutations in Drug-Resistant Basal Cell Carcinoma.** *journal of investigative dermatology*
Atwood, S. X., Sarin, K. Y., Li, J. R., Yao, C. Y., Urman, N. M., Chang, A. L., Tang, J. Y., Oro, A. E.
2015; 135 (8): 2138-2141
 - **Overall and progression-free survival of stage 4 cutaneous squamous cell carcinoma at a single large referral center** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Zhu, G., Chang, A.
2015; 73 (1): 165-66
 - **Management of Cutaneous and Extracutaneous Side Effects of Smoothed Inhibitor Therapy for Advanced Basal Cell Carcinoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Mohan, S. V., Chang, A. L.
2015; 21 (12): 2677-83
 - **Assessment of the Genetic Basis of Rosacea by Genome-Wide Association Study** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*
Chang, A. L., Raber, I., Xu, J., Li, R., Spitale, R., Chen, J., Kiefer, A. K., Tian, C., Eriksson, N. K., Hinds, D. A., Tung, J. Y.
2015; 135 (6): 1548-1555
 - **Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Sekulic, A., Migden, M. R., Lewis, K., Hainsworth, J. D., Solomon, J. A., Yoo, S., Arron, S. T., Friedlander, P. A., Marmur, E., Rudin, C. M., Chang, A. L., Dirix, L., Hou, et al
2015; 72 (6): 1021-?
 - **Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial** *LANCET ONCOLOGY*

- Migden, M. R., Guminski, A., Gutzmer, R., Dirix, L., Lewis, K. D., Combemale, P., Herd, R. M., Kudchadkar, R., Trefzer, U., Gogov, S., Pallaud, C., Yi, T., Mone, et al
2015; 16 (6): 716–28
- **A new functional validation assay to measure resistance drivers in patient BCCs** *Annual Meeting of the Society-for-Investigative-Dermatology*
Whitson, R., Atwood, S., SARIN, K., Li, J., Kim, G., Rezaee, M., ALLY, M. S., Yao, C., Chang, A. S., Tang, J. Y., Oro, A.
NATURE PUBLISHING GROUP.2015: S23–S23
 - **Hyaluronan synthase 2 antisense transcript level associates with human skin youthfulness as identified by transcriptome sequencing**
Xu, J., Flynn, R. A., Spitale, R., Torre, E., Li, R., Kern, D. G., Knaggs, H., Chang, H., Chang, A. S.
NATURE PUBLISHING GROUP.2015: S45
 - **Rolling the genetic dice: Neutral and deleterious SMO mutations in drug-resistant basal cell carcinoma**
Atwood, S., Sarin, K., Li, J., Yao, C., Urman, N. M., Chang, A. S., Tang, J. Y., Oro, A.
NATURE PUBLISHING GROUP.2015: S21
 - **Lack of resistant SMO mutations and decreased mutational load of Gorlin-associated basal cell cancers explain marked response to smoothed inhibitors**
Sarin, K., Rezaee, M., Jaju, P., Chang, A. S., Oro, A., Epstein, E., Tang, J. Y.
NATURE PUBLISHING GROUP.2015: S23
 - **Combined treatment with arsenic trioxide and itraconazole inhibits the hedgehog pathway in patients with refractory metastatic basal cell carcinoma: results from a pilot trial**
Ransohoff, K. J., Ally, M. S., Sarin, K., Atwood, S., Rezaee, M., Bailey, I., Beachy, P., Chang, A. S., Oro, A., Colevas, D., Tang, J. Y.
NATURE PUBLISHING GROUP.2015: S30
 - **Identification of a unique gene expression profile in older women with youthful skin**
Chang, A., Spitale, R., Torre, E., Li, R., Kern, D., Knaggs, H., Xu, J.
MOSBY-ELSEVIER.2015: AB24
 - **Smoothed variants explain the majority of drug resistance in Basal cell carcinoma.** *Cancer cell*
Atwood, S. X., Sarin, K. Y., Whitson, R. J., Li, J. R., Kim, G., Rezaee, M., Ally, M. S., Kim, J., Yao, C., Chang, A. L., Oro, A. E., Tang, J. Y.
2015; 27 (3): 342-353
 - **Advances in Geriatric Dermatology**
edited by Chang, A. S.
Springer International Publishing.2015
 - **Novel GATA6 Mutations in Patients with Pancreatic Agenesis and Congenital Heart Malformations.** *PloS one*
Chao, C. S., McKnight, K. D., Cox, K. L., Chang, A. L., Kim, S. K., Feldman, B. J.
2015; 10 (2): e0118449
 - **An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Ally, M. S., Aasi, S., Wysong, A., Teng, C., Anderson, E., Bailey-Healy, I., Oro, A., Kim, J., Chang, A. L., Tang, J. Y.
2014; 71 (5): 904-U304
 - **Two Different Scenarios of Squamous Cell Carcinoma Within Advanced Basal Cell Carcinomas Cases Illustrating the Importance of Serial Biopsy During Vismodegib Usage** *JAMA DERMATOLOGY*
Zhu, G. A., Sundram, U., Chang, A. L.
2014; 150 (9): 970-973
 - **Low rate of dermatology outpatient visits in Asian-Americans: an initial survey study for associated patient-related factors** *BMC DERMATOLOGY*
Lingala, B., Li, S., Wysong, A., Truong, A. K., Kim, D., Chang, A. S.
2014; 14
 - **Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449)** *AUSTRALASIAN JOURNAL OF DERMATOLOGY*
Meani, R. E., Lim, S., Chang, A. L., Kelly, J. W.
2014; 55 (3): 218-221

- **Combined treatment with arsenic trioxide and itraconazole inhibits the Hedgehog pathway in patients with refractory metastatic basal cell carcinoma: Results from a pilot trial**
Rezaee, M., Ally, M. S., Sarin, K., Atwood, S., Chang, A. S., Oro, A., Bailey, I., Colevas, D., Tang, J. Y.
NATURE PUBLISHING GROUP.2014: S2
- **Patient With Gorlin Syndrome and Metastatic Basal Cell Carcinoma Refractory to Smoothened Inhibitors.** *JAMA dermatology*
Zhu, G. A., Li, A. S., Chang, A. L.
2014
- **Overall and progression-free survival in metastatic basosquamous cancer: A case series.** *Journal of the American Academy of Dermatology*
Zhu, G. A., Danial, C., Liu, A., Li, S., Su Chang, A. L.
2014; 70 (6): 1145-1146
- **Precision medicine and precision therapeutics: Hedgehog signaling pathway, basal cell carcinoma and beyond.** *Seminars in cutaneous medicine and surgery*
Mohan, S. V., Chang, A. L.
2014; 33 (2): 68-71
- **Only Skin Deep: Optimism and Public Self-Consciousness Did Not Associate With the Placebo Response in a Dermatology Clinical Trial** *JOURNAL OF DRUGS IN DERMATOLOGY*
Garshick, M. K., Chang, A. L., Kimball, A. B.
2014; 13 (6): 719-722
- **Identification of unique gene expression profiles in older women with youthful appearing skin**
Spitale, R., Li, R., Torre, E., Kern, D. G., Knaggs, H., Chang, A. S.
NATURE PUBLISHING GROUP.2014: S135
- **A useable and comprehensive tool to estimate cumulative lifetime ultraviolet exposure**
Li, A., Chang, A. S., Zhu, G. A.
MOSBY-ELSEVIER.2014: AB153
- **Unexpected complexity in smoothened variants associated with drug resistant basal cell carcinoma**
Sarin, K., Atwood, S., Li, J., Chang, A. S., Oro, A., Tang, J.
NATURE PUBLISHING GROUP.2014: S36
- **Open-label pilot study of LDE225 in advanced basal cell carcinoma patients who have been treated previously with a non-LDE225 Smoothened inhibitor**
Chang, A. S., Oro, A.
NATURE PUBLISHING GROUP.2014: S101
- **Identification of genes promoting skin youthfulness by genome-wide association study.** *journal of investigative dermatology*
Chang, A. L., Atzmon, G., Bergman, A., Brugmann, S., Atwood, S. X., Chang, H. Y., Barzilai, N.
2014; 134 (3): 651-657
- **Oral smoothened inhibitor for advanced basal cell carcinoma of the hand: a case report.** *Hand (New York, N.Y.)*
Zhu, G. A., Chen, A., Chang, A. L.
2014; 9 (1): 127-128
- **Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations.** *Current dermatology reports*
Mohan, S. V., Chang, A. L.
2014; 3: 40-45
- **Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Chang, A. L., Solomon, J. A., Hainsworth, J. D., Goldberg, L., McKenna, E., Day, B., Chen, D. M., Weiss, G. J.
2014; 70 (1): 60-69
- **Special Patient Populations MODERATE TO SEVERE PSORIASIS, 4TH EDITION**
Butler, D. C., Kamangar, F., Levin, E. C., Koo, J. Y. M., Chang, A. L. S.
edited by Koo, J. Y., Levin, E. C., Leon, A., Wu, J. J., Gottlieb, A. B.

2014; 335-348

- **Low rate of dermatology outpatient visits in Asian-Americans: an initial survey study for associated patient-related factors.** *BMC dermatology*
Lingala, B., Li, S., Wysong, A., Truong, A. K., Kim, D., Chang, A. L.
2014; 14 (1): 13-?
- **Dermatologic Clinical Trials: A Practical Approach** *Clinical Dermatology Trials 101: A Primer for Dermatologists*
Mohan, S., Chang, A. S.
Springer International Publishing.2014; 1st: 47-58
- **Vismodegib for Periocular and Orbital Basal Cell Carcinoma** *JAMA OPHTHALMOLOGY*
Gill, H. S., Moscato, E. E., Chang, A. S., Soon, S., Silkiss, R. Z.
2013; 131 (12): 1591-94
- **Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.** *British journal of dermatology*
Danial, C., Lingala, B., Balise, R., Oro, A. E., Reddy, S., Colevas, A., Chang, A. L.
2013; 169 (3): 673-676
- **Rejuvenation of Gene Expression Pattern of Aged Human Skin by Broadband Light Treatment: A Pilot Study (vol 133, pg 394, 2013)** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*
Chang, A. S., Bitter, P. H., Qu, K., Lin, M., Rapicavoli, N. A., Chang, H. Y.
2013; 133 (6): 1691
- **Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors** *CLINICAL CANCER RESEARCH*
Jimeno, A., Weiss, G. J., Miller, W. H., Gettinger, S., Eigl, B. J. C., Chang, A. S., Dunbar, J., Devens, S., Faia, K., Skliris, G., Kutok, J., Lewis, K. D., Tibes, et al
2013; 19 (10): 2766-74
- **Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced Basal cell carcinoma and resistant Basal carcinomas in gorlin syndrome.** *JAMA dermatology (Chicago, Ill.)*
Chang, A. L., Atwood, S. X., Tartar, D. M., Oro, A. E.
2013; 149 (5): 639-641
- **High incidence of striae distensae in pediatric adolescent patients on high dose corticosteroids for treatment of rheumatic disease and effect on adherence to prescribed regimen**
Washington, N. T., Chang, A. S.
NATURE PUBLISHING GROUP.2013: S98
- **Vismodegib as an adjuvant to surgery for basal cell carcinomas** *International Investigative Dermatology Meeting*
ALLY, M. S., Aasi, S., Chang, A., Teng, C., Anderson, E. M., Bailey, I., Wysong, A., Kim, J., Tang, J. Y.
NATURE PUBLISHING GROUP.2013: S178-S178
- **Geriatric dermatology Part I. Geriatric pharmacology for the dermatologist** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Endo, J. O., Wong, J. W., Norman, R. A., Chang, A. L.
2013; 68 (4)
- **Rejuvenation of Gene Expression Pattern of Aged Human Skin by Broadband Light Treatment: A Pilot Study** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*
Chang, A. L., Bitter, P. H., Qu, K., Lin, M., Rapicavoli, N. A., Chang, H. Y.
2013; 133 (2): 394-402
- **New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: A Report of 2 Cases** *JAMA DERMATOLOGY*
Aasi, S., Silkiss, R., Tang, J. Y., Wysong, A., Liu, A., Epstein, E., Oro, A. E., Chang, A. L.
2013; 149 (2): 242-243
- **Geriatric dermatology: Part II. Risk factors and cutaneous signs of elder mistreatment for the dermatologist** *Journal of the American Academy of Dermatology*
Chang, A. S., Wong, J. W., Endo, J. O., Norman, R. A.
2013; 68 (4): 533. E1-533.E10

- **Geriatric dermatology review: Major changes in skin function in older patients and their contribution to common clinical challenges.** *Journal of the American Medical Directors Association*
Chang, A. L., Wong, J. W., Endo, J. O., Norman, R. A.
2013; 14 (10): 724–30
- **A simple intervention to reinforce awareness of tanning bed use and skin cancer in non-medical skin care professionals in Southern California** *INTERNATIONAL JOURNAL OF DERMATOLOGY*
Ng, A. T., Chang, A. L., Cockburn, M., Peng, D. H.
2012; 51 (11): 1307-1312
- **Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma** *ARCHIVES OF DERMATOLOGY*
Chang, A. S., Oro, A. E.
2012; 148 (11): 1324–25
- **Hedgehog pathway inhibition and the race against tumor evolution** *JOURNAL OF CELL BIOLOGY*
Atwood, S. X., Chang, A. L., Oro, A. E.
2012; 199 (2): 193-197
- **Native American skin offerings mistaken for acne scars in a college undergraduate.** *Archives of dermatology*
Truong, A., Wong, J. W., Chang, A. L.
2012; 148 (10): 1214-1215
- **EXPANDED ACCESS STUDY OF ADVANCED BCC PATIENTS TREATED WITH THE HEDGEHOG-PATHWAY INHIBITOR VISMODEGIB** *37th Congress of the European-Society-for-Medical-Oncology (ESMO)*
Weiss, G. J., Oro, A., Chang, A. L., Solomon, J. A., Lorusso, P. M., Hamid, O., Chen, D. M., McKenna, E., Feng, S., Hainsworth, J. D.
OXFORD UNIV PRESS.2012: 362–362
- **Translocation Affecting Sonic Hedgehog Genes in Basal-Cell Carcinoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Gomez-Ospina, N., Chang, A. L., Qu, K., Oro, A. E.
2012; 366 (23): 2233-2234
- **Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Sekulic, A., Migden, M. R., Oro, A. E., Dirix, L., Lewis, K. D., Hainsworth, J. D., Solomon, J. A., Yoo, S., Arron, S. T., Friedlander, P. A., Marmur, E., Rudin, C. M., Chang, et al
2012; 366 (23): 2171-2179
- **Identification of genes promoting exceptional skin youthfulness** *75th Annual Meeting of the Society-for-Investigative-Dermatology*
Chang, A. S., Atzmon, G., Bergman, A., Chang, H. Y., Barzilai, N.
NATURE PUBLISHING GROUP.2012: S65–S65
- **Rejuvenation of gene expression patterns in aged human skin with broadband light treatment**
Chang, A. S., Bitter, P., Qu, K., Chang, H. Y.
NATURE PUBLISHING GROUP.2012: S65
- **SMO inhibitor effectiveness in a patient with a SHH locus translocation causing holoprosencephaly and basal cell carcinomas**
Gomez-Ospina, N., Bangs, C. D., Qu, K., Chang, A. L., Oro, A. E.
NATURE PUBLISHING GROUP.2012: S28
- **Efficacy and safety of vismodegib in advanced basal cell carcinoma**
Chang, A., Sekulic, A., Migden, M. R., Hauschild, A., Lewis, K., Hainsworth, J. D., Yoo, S., Dirix, L., Hou, J., Mackey, H., Oro, A. E.
NATURE PUBLISHING GROUP.2012: S93
- **Hedgehog pathway inhibitor Vismodegib (GDC-0449) in metastatic basal cell carcinoma**
Lim, S. W., Chang, A. S., Kelly, J. W.
WILEY-BLACKWELL.2012: 43–44
- **Dramatically improved overall survival and predictors of disease in 17 metastatic basal cell carcinoma patients** *75th Annual Meeting of the Society-for-Investigative-Dermatology*
Danial, C., Lingala, B., Oro, A. E., Chang, A. S.
NATURE PUBLISHING GROUP.2012: S39–S39

- **Transcriptional profiling to identify genes controlling human skin aging** *70th Annual Meeting of the American-Academy-of-Dermatology (AAD)*
Chang, A. L., Kern, D., Knaggs, H., Gierman, H., Kim, S.
MOSBY-ELSEVIER.2012: AB32-AB32
- **An Exploratory Study to Determine the Association Between Assessed Facial Skin Aging and Plasma Isoprostane Levels in Middle-Aged Japanese Women** *DERMATOLOGIC SURGERY*
Chang, A. L., Lingala, B., Chang, T. C., Kern, D. G., Wood, S. M., Toyoda, H., Knaggs, H. E.
2012; 38 (3): 462-470
- **A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Assess the Efficacy and Safety of Clindamycin 1.2% and Tretinoin 0.025% Combination Gel for the Treatment of Acne Rosacea Over 12 Weeks** *JOURNAL OF DRUGS IN DERMATOLOGY*
Chang, A. L., Alora-Palli, M., Lima, X. T., Chang, T. C., Cheng, C., Chung, C. M., Amir, O., Kimball, A. B.
2012; 11 (3): 333-339
- **Differential effects of dietary supplements on metabolomic profile of smokers versus non-smokers** *Genome Medicine*
Spitale, R. C., Cheng, M. Y., Chun, K. A., Gorell, E. S., Munoz, C. A., Kern, D. G., Wood, S. M., Knaggs, H. E., Beebe, K. D., Chang, A. S.
2012; 4 (2)
- **A Little Known but Potentially Life-threatening Association of Bullous Pemphigoid and Acquired Hemophilia: Case Report and Review of the Literature**
Nguyen, C., Gordan, J. S., Chang, A. S.
Journal of Clinical & Experimental Dermatology Research.
2012 ; Commentary (ISSN:2155-9554): 1-3
- **More than just a coincidence: Herpes zoster and acne rosacea appearing together as Wolf's isotopic response in an Asian female**
Fijalkowski, N., Wysong, A., Khuu, P., Chang, A. S.
International Journal of Case Reports and Images.
2012 ; Case Report (Volume 3, Issue 2): 24-27
- **Stratification of Highest-Risk Patients with Chronic Skin Ulcers in a Stanford Retrospective Cohort Includes Diabetes, Need for Systemic Antibiotics, and Albumin Levels** *Ulcers*
Amir, O., Liu, A., Chang, A. S.
2012; 2012 (1): 7
- **A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.**
Rudin, C. M., Jimeno, A., Miller, W. H., Eigl, B. J., Gettinger, S. N., Chang, A. S., Faia, K., Sweeney, J., Loewen, G., Ross, R. W., Weiss, G. J.
AMER SOC CLINICAL ONCOLOGY.2011
- **Not so positive: Optimism and public self-consciousness were not associated with the placebo response in a rosacea trial.** *71st Annual Meeting of the Society-for-Investigative-Dermatology*
Kardos, M., Kim, G., Chang, A. S., Kimball, A. B.
NATURE PUBLISHING GROUP.2011: S37-S37
- **Association of skin aging severity with blood isoprostane levels in healthy middle-aged Japanese women** *71st Annual Meeting of the Society-for-Investigative-Dermatology*
Chang, T. C., Lingala, B., Kern, D. G., Wood, S. M., Toyoda, H., Knaggs, H., Chang, A. S.
NATURE PUBLISHING GROUP.2011: S85-S85
- **Getting the word out: A fast intervention to educate nonmedical skin care professionals at salons and spas in southern California about tanning bed usage and skin cancer** *69th Annual Meeting of the American-Academy-of-Dermatology*
Ng, A., Chang, A. L., Peng, D.
MOSBY-ELSEVIER.2011: AB78-AB78
- **Association of facial skin aging and vitamin D levels in healthy middle-aged white women**
Chang, A., Tang, J., Amir, O., Fu, T.
MOSBY-ELSEVIER.2011: AB2
- **Facial skin aging and association with blood markers of oxidative stress**
Chang, A., Morre, D., Kern, D., Morre, D., Wood, S. M.
MOSBY-ELSEVIER.2011: AB21

- **A case of Cinderella: erythema dyschromicum perstans (ashy dermatosis or dermatosis cinecienta)**
Munoz, C., Chang, A. S.
SKINmed: Dermatology for the Clinician (Published by Pulse Marketing and Communications, LLC.).
2011 ; Case Studies (Volume 9, Issue 1): 63-64
- **Association of facial skin aging and vitamin D levels in middle-aged white women** *CANCER CAUSES & CONTROL*
Chang, A. L., Fu, T., Amir, O., Tang, J. Y.
2010; 21 (12): 2315-2316
- **A PHASE 1 STUDY OF IPI-926, AN INHIBITOR OF THE HEDGEHOG PATHWAY, IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC SOLID TUMORS**
Rudin, C. M., Weiss, G. J., Chang, A., Gettinger, S., Miller, W. H., Eigl, B., Savage, A., Loewen, G., Ross, R. W., Jimeno, A.
OXFORD UNIV PRESS.2010: 164
- **Initial clinical experience using a novel ultraportable negative pressure wound therapy device.** *Wounds : a compendium of clinical research and practice*
Fong, K. D., Hu, D., Eichstadt, S. L., Gorell, E., Munoz, C. A., Lorenz, H. P., Chang, A. L.
2010; 22 (9): 230-6
- **A single-blind pilot study of oral antioxidant supplementation on skin aging parameters and age associated blood metabolites in female smokers** *68th Annual Meeting of the American-Academy-of-Dermatology*
Chang, A. L., Munoz, C., Kern, D., Gorell, E., Wood, S.
MOSBY-ELSEVIER.2010: AB19-AB19
- **A Two-Year, Double-Blind, Randomized Placebo-Controlled Trial of Oral Green Tea Polyphenols on the Long-Term Clinical and Histologic Appearance of Photoaging Skin** *DERMATOLOGIC SURGERY*
Janjua, R., Munoz, C., Gorell, E., Rehmus, W., Egbert, B., Kern, D., Chang, A. L.
2009; 35 (7): 1057-1065
- **Preventing Diabetic Skin Ulcers in Latinos-No Small Feat: Development of a Spanish and English Survey for Fast Assessment of Lower Extremity Skin Care Practices** *ARCHIVES OF DERMATOLOGY*
Munoz, C., Chang, A. S.
2009; 145 (4): 486-88
- **A 2-year, double-blind, randomized, placebo-controlled trial of oral green tea polyphenols on the long-term clinical and histologic appearance of photoaging skin**
Chang, A., Egbert, B., Munoz, C., Janjua, R., Rehmus, W.
MOSBY-ELSEVIER.2009: AB29
- **Oral contraceptives for acne and sexual practices** *JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY*
Abuabara, K., Chang, A. S.
2009; 60 (3): 515-16
- **Adoption of Western Culture by Californian Asian Americans: Attitudes and Practices Promoting Sun Exposure**
Gorell, E., Lee, C., Munoz, C., Chang, A. S.
JAMA Dermatology.
2009 ; Comparative Study (Volume 145, Issue 5): 552-556
- **Alefacept for erosive lichen planus: A case series** *JOURNAL OF DRUGS IN DERMATOLOGY*
Chang, A. L., Badger, J., Rehmus, W., Kimball, A. B.
2008; 7 (4): 379-383
- **Factors affecting sun protection and skin cancer prevention knowledge, attitudes and practices in Asian-Americans living in Northern California** *International Investigative Dermatology Meeting*
Chang, A. S., Gorell, E. S., Lee, C., Munoz, C. A.
NATURE PUBLISHING GROUP.2008: S84-S84
- **A case of argyria after colloidal silver ingestion** *JOURNAL OF CUTANEOUS PATHOLOGY*
Chang, A. L., Khosravi, V., Egbert, B.
2006; 33 (12): 809-811

- **Academic dermatology realities: Results from a 2002 survey of AADA members**
Chang, A. L., Kimball, A., Resneck, J.
MOSBY, INC.2005: P99
- **Risk factors associated with striae gravidarum** *65th Annual Meeting of the Society-for-Investigative-Dermatology*
Chang, A. L., Agredano, Y. Z., Kimball, A. B.
MOSBY-ELSEVIER.2004: 881-85
- **Risk factors associated with striae gravidarum** *65th Annual Meeting of the Society-for-Investigative-Dermatology*
Chang, A. S., Agredano, Y. Z., Kimball, A. B.
NATURE PUBLISHING GROUP.2004: A60-A60
- **Salpingectomy or proximal tubal occlusion of unilateral hydrosalpinx increases the potential for spontaneous pregnancy** *HUMAN REPRODUCTION*
Sagoskin, A. W., Lessey, B. A., Mottla, G. L., Richter, K. S., Chetkowski, R. J., Chang, A. S., Levy, M. J., Stillman, R. J.
2003; 18 (12): 2634-2637
- **Obstetric attending physician characteristics and their impact on vacuum and forceps delivery rates: University of California at San Francisco experience from 1977 to 1999**
Chang, A. L., Noah, M. S., Laros, R. K.
MOSBY, INC.2002: 1299-1303
- **Talin and vinculin play distinct roles in filopodial motility in the neuronal growth cone** *Journal of Cell Biology (JCB)*
Sydor, A. M., Su A.L., Wang, F. S., Jay, D. G.
1996; 134 (5): 1197-1207
- **Chromophore-assisted laser inactivation of patched protein switches cell fate in the larval visual system of Drosophila.** *Proceedings of the National Academy of Sciences of the United States of America (PNAS)*
Schmucker, D., Su A.L., Beermann, A., Jay, D. G.
1994; 91 (7): 2664-2668